These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, Settleman J. Cancer Res; 2008 Jun 15; 68(12):4853-61. PubMed ID: 18559533 [Abstract] [Full Text] [Related]
9. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. Peng SB, Henry JR, Kaufman MD, Lu WP, Smith BD, Vogeti S, Rutkoski TJ, Wise S, Chun L, Zhang Y, Van Horn RD, Yin T, Zhang X, Yadav V, Chen SH, Gong X, Ma X, Webster Y, Buchanan S, Mochalkin I, Huber L, Kays L, Donoho GP, Walgren J, McCann D, Patel P, Conti I, Plowman GD, Starling JJ, Flynn DL. Cancer Cell; 2015 Sep 14; 28(3):384-98. PubMed ID: 26343583 [Abstract] [Full Text] [Related]
10. A novel phosphorylation site involved in dissociating RAF kinase from the scaffolding protein 14-3-3 and disrupting RAF dimerization. Yu A, Nguyen DH, Nguyen TJ, Wang Z. J Biol Chem; 2023 Oct 14; 299(10):105188. PubMed ID: 37625591 [Abstract] [Full Text] [Related]
11. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Smalley KS, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R, Van Belle P, Elder DE, Wang Y, Nathanson KL, Herlyn M. Oncogene; 2009 Jan 08; 28(1):85-94. PubMed ID: 18794803 [Abstract] [Full Text] [Related]
12. Active Ras induces heterodimerization of cRaf and BRaf. Weber CK, Slupsky JR, Kalmes HA, Rapp UR. Cancer Res; 2001 May 01; 61(9):3595-8. PubMed ID: 11325826 [Abstract] [Full Text] [Related]
13. Selective CRAF Inhibition Elicits Transactivation. Morgan CW, Dale IL, Thomas AP, Hunt J, Chin JW. J Am Chem Soc; 2021 Mar 31; 143(12):4600-4606. PubMed ID: 33750116 [Abstract] [Full Text] [Related]
14. CRAF dimerization with ARAF regulates KRAS-driven tumor growth. Venkatanarayan A, Liang J, Yen I, Shanahan F, Haley B, Phu L, Verschueren E, Hinkle TB, Kan D, Segal E, Long JE, Lima T, Liau NPD, Sudhamsu J, Li J, Klijn C, Piskol R, Junttila MR, Shaw AS, Merchant M, Chang MT, Kirkpatrick DS, Malek S. Cell Rep; 2022 Feb 08; 38(6):110351. PubMed ID: 35139374 [Abstract] [Full Text] [Related]
15. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, Huber L, Peng SB, Stancato LF. Oncotarget; 2017 Feb 07; 8(6):9251-9266. PubMed ID: 27999210 [Abstract] [Full Text] [Related]
17. A MEK-independent role for CRAF in mitosis and tumor progression. Mielgo A, Seguin L, Huang M, Camargo MF, Anand S, Franovic A, Weis SM, Advani SJ, Murphy EA, Cheresh DA. Nat Med; 2011 Nov 13; 17(12):1641-5. PubMed ID: 22081024 [Abstract] [Full Text] [Related]
18. Discovery of highly selective CRAF inhibitors, 3-carboxamido-2H-indazole-6-arylamide: In silico FBLD design, synthesis and evaluation. Aman W, Lee J, Kim M, Yang S, Jung H, Hah JM. Bioorg Med Chem Lett; 2016 Feb 15; 26(4):1188-92. PubMed ID: 26810260 [Abstract] [Full Text] [Related]